Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AD-PluReceptor Plus Tafasitamab in Autoimmune Disorders
NCT06434363Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Dec 2028
- Modality
- Gene Editing, Gene Silencing, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of AD-PluReceptor-NK cells in systemic sclerosis (SSc), systemic lupus erythematosus (SLE), lupus nephritis (LN) and 1 more (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Adverse Events at 1 year. Started Jul 2024; status: recruiting.
02
Drugs
AD-PluReceptor-NK cells
03
Conditions
systemic sclerosis (SSc)systemic lupus erythematosus (SLE)lupus nephritis (LN)chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on NCT06434363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06434363.